Catalyst Dossier · compiled by CeliA 🧫
Werewolf Therapeutics, Inc. (HOWL)
Pharmaceutical Preparations · market cap $17M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Werewolf Therapeutics (HOWL) is a clinical-stage pharmaceutical company with a market cap of ~$18M and 39 employees, trading at ~$0.37/share. Its sole disclosed pipeline asset is WTX-330, currently in Phase 2 for advanced or metastatic solid tumors, with a mechanism of action not specified in available data. The company holds $46.5M in cash against a 13.1-month runway, implying a meaningful financing decision ahead of or shortly after mid-2027.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| WTX-330 | Phase 2 | Advanced or Metastatic Solid Tumors |
Price & technical context
3-month
-39.6%
6-month
-46.8%
12-month
-67.6%
52-wk range
$0.31–$2.19
vs 50-day MA
+0.8%
vs 200-day MA
-45.0%
Realized vol
109.4%
Max drawdown
-91.5%
Daily closes through 2026-08-12. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HOWL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.